Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational

The Indiana Myeloma Registry

NCT03616483
Conditions
Plasma Cell Dyscrasias
Interventions
This is a non-interventional trial
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Refractory Multiple Myeloma
Interventions
dinaciclib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Detroit, Michigan + 2 more
Conditions
Multiple Myeloma
Interventions
Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Conditions
Multiple Myeloma
Interventions
MRZ 0.5 mg/m^2
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more
Conditions
Cardio-Pulmonary Bypass
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Multiple Myeloma
Interventions
plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Conditions
Multiple Myeloma
Interventions
Discontinue maintenance therapy SOC
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Drug
Lead sponsor
Arch Oncology
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Conditions
Appetite and General Nutritional Disorders
Interventions
Exercise or Sedentary
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 39 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Simvastatin and zoledronic acid
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Multiple Myeloma
Interventions
CC-5013 (Revlimid™), bortezomib
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Multiple Myeloma
Interventions
Elranatamab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
Interventions
Ramantamig, Daratumumab, Pomalidomide, Lenalidomide, JNJ-102299639
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Denver, Colorado • Atlanta, Georgia
Conditions
Multiple Myeloma
Interventions
TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more
Conditions
Multiple Myeloma
Interventions
Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
Drug · Biological · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 11 more
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
Interventions
Ibrutinib, Daratumumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
MK-6916, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hepatic Function Abnormal
Interventions
tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research

NCT01382615
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Completed No phase listed Observational Accepts healthy volunteers

Effects of Storage on Lactate in Blood Samples

NCT00011050
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
3
States / cities
San Francisco, California • Indianapolis, Indiana